2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Language English Country England, Great Britain Media print
Document type Journal Article
PubMed
36017568
DOI
10.1093/eurheartj/ehac244
PII: 6673995
Knihovny.cz E-resources
- Keywords
- Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Anthracycline, Arrhythmias, Atrial fibrillation, Biomarkers, Cancer, Cancer survivors, Carcinoid syndrome, Cardiac magnetic resonance, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Coronary artery disease, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Strain, Thrombosis, Trastuzumab, Valvular heart disease, Vascular endothelial growth factor inhibitors (VEGFi), Venous thromboembolism,
- MeSH
- Hematology * MeSH
- Medical Oncology MeSH
- Humans MeSH
- Neoplasms * drug therapy MeSH
- Antineoplastic Agents * therapeutic use MeSH
- Radiation Oncology * MeSH
- Heart MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antineoplastic Agents * MeSH
References provided by Crossref.org
The Digital Revolution in Medicine: Applications in Cardio-Oncology
Cardiac Conduction System as an OAR in Radiation Therapy: Doses to SA/AV Nodes and Their Reduction